SIHUAN PHARM
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-10-06
- Employees
- 2.6K
- Market Cap
- -
- Website
- http://www.sihuanpharm.com
- Introduction
Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.
Clinical Trials
23
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: XZP-5809-TT1 Tablet
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04622072
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Beijing cancer hospital, Beijing, Beijing, China
🇨🇳Henan university of science and technology first hospital, Luoyang, Henan, China
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
- Conditions
- Metastasis Solid TumorsAdvanced Breast Cancer
- Interventions
- Drug: XZP-3287;Letrozole;Anastrozole;Fulvestrant
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT04539496
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Complicated Urinary Tract Infection Including Acute Pyelonephritis
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT04505683
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
- Conditions
- Duodenal Ulcer，DU
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04503629
- Locations
- 🇨🇳
The Fisrst Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China
Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C]-Anaprazole Sodium enteric-coated capsule
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04476394
- Prev
- 1
- 2
- 3
- 4
- 5
- Next